We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 in a research note issued to investors on Thursday,Benzinga reports.

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

25 analysts have shared their evaluations of Vertex Pharmaceuticals VRTX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

34,658 people played the daily Crossword recently. Can you solve it faster than others?34,658 people played the daily Crossword recently. Can you solve it faster than others? A 55-year-old ...

VRTX stock opened at $462.58 on Tuesday. The firm has a fifty day moving average price of $435.70 and a 200 day moving average price of $461.79. Vertex Pharmaceuticals has a fifty-two week low of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

LONDON, January 31, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...